Zeneca Files NDA for Arimidex

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 7
Volume 4
Issue 7

WILMINGTON, Del--Zeneca Pharmaceuticals has filed a new drug application (NDA) for the use of Arimidex (anastrozole) tablets for the treatment of advanced breast cancer in postmenopausal women who have progressed following therapy with tamoxifen (Nolvadex).

WILMINGTON, Del--Zeneca Pharmaceuticals has filed a new drug application(NDA) for the use of Arimidex (anastrozole) tablets for the treatmentof advanced breast cancer in postmenopausal women who have progressedfollowing therapy with tamoxifen (Nolvadex).

Arimidex, a nonsteroidal compound, is one of the first of a newclass of selective oral aromatase inhibitors, designed to reducethe production of estrogen. The NDA is based on randomized, controlledtrials involving 764 women with advanced breast cancer, the companysaid.

Articles in this issue
ODAC Recommends Accelerated FDA Approval of Ethyol for Cytoprotection
House Panel Holds Hearing on Self-Referral
Health-Related Legislation
Mitoguazone Appears Promising in HIV-Associated Refractory NHL
Responses to Anti-HER2 MoAb Seen
NCI Committed to Increasing Minority Participation in Clinical Trials
MoAb May Improve Detection of Colon And Rectal Cancer
Zeneca Files NDA for Arimidex
Cord Blood is Used as Source of Stem Cells for Pediatric Transplantation
Gemcitabine/Cisplatin Shows Good Response Rate And Favorable Toxicity Profile in Advanced NSCLC
HCFA Needs to Do More to Prevent Medicare/Medicaid Fraud and Abuse
M.D. Anderson Holds First Cancer Meeting in Spanish
Molecular Markers Predict Clinical Outcome
NCAB Has Concerns About Future of Clinical Research
IP Interleukin-2 Shows Durable Responses in Ovarian Cancer
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
FLEX study findings show that the MammaPrint Index was predictive of 5-year DRFI for endocrine therapy with or without chemotherapy in early breast cancer.

MammaPrint Displays Predictive Utility for Chemo in HR+/HER2– Breast Cancer

Roman Fabbricatore
August 13th 2025
Article

FLEX study findings show that the MammaPrint Index was predictive of 5-year DRFI for endocrine therapy with or without chemotherapy in early breast cancer.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

The decision is based on phase 3 VERITAC-2 trial data showing a significant PFS improvement vs fulvestrant in ESR1-mutant ER+/HER2– breast cancer.

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2– Breast Cancer

Roman Fabbricatore
August 11th 2025
Article

The decision is based on phase 3 VERITAC-2 trial data showing a significant PFS improvement vs fulvestrant in ESR1-mutant ER+/HER2– breast cancer.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic

Breast Medical Oncologist Returns Home to Serve in Multidisciplinary Clinic

Ariana Pelosci
July 29th 2025
Article

Priya Jayachandran, MD, FACP, spoke about her new position at El Camino Health as well as her career as a breast oncologist.

Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.

Gedatolisib Combos Improve PFS in Advanced PIK3CA Wild-Type Breast Cancer

Tim Cortese
July 29th 2025
Article

Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.